Journal of Clinical Oncology最新文献

{"title":"Should We Call Every Cancer a Rare Cancer?","authors":"Chadi Nabhan, Vivek Subbiah","doi":"10.1200/JCO-26-00596","DOIUrl":"10.1200/JCO-26-00596","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2891-2894"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?","authors":"Juan Yang, Fubing Yu, Sheng Zheng","doi":"10.1200/JCO-26-00177","DOIUrl":"10.1200/JCO-26-00177","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2975-2976"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.","authors":"Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie G J Robbrecht, Jiří Tomášek, Cagatay Arslan, Mustafa Özgüroğlu, Panoraia Arni, Frederic Bigot, Sun Young Kim, Yoichi Naito, Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Ning Ma, Jeremy Scarato, Jeffrey S Ross, Holger Moch, Linda Mileshkin","doi":"10.1200/JCO-26-02285","DOIUrl":"10.1200/JCO-26-02285","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2980"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial.","authors":"Yan Ma, Linda E Carlson, Jennifer M Jones, Oluwaseyi A Lawal, Devesh Oberoi, Katherine-Ann Piedalue, Daniel Santa Mina, Michael Speca, Peter M Wayne","doi":"10.1200/JCO-25-01967","DOIUrl":"10.1200/JCO-25-01967","url":null,"abstract":"<p><strong>Purpose: </strong>Sleep, fatigue, and pain are common symptoms in cancer survivors. Mindfulness-based cancer recovery (MBCR) and Tai Chi/Qigong (TCQ) are beneficial for these conditions, but have not been studied together. The Mindfulness and Tai Chi for Cancer Health (MATCH) study was designed to incorporate innovative design features, including patient choice, while evaluating two interventions for distressed cancer survivors with predefined secondary outcomes, including sleep, fatigue, and pain.</p><p><strong>Methods: </strong>Participants chose one of the two interventions or chose to be randomly assigned into either intervention, then were further randomly assigned into immediate intervention or waitlist groups. We evaluated the efficacy of MBCR and TCQ, whether participants' choices affected intervention effects, and correlations among changes in sleep, fatigue, and pain.</p><p><strong>Results: </strong>Participants (N = 587) were on average 60.7 years, with multiple types and stages of cancer. At postintervention, compared with waitlist controls, the TCQ group had an average improvement of 1.9 points on the sleep quality scale, which remained statistically significant compared with controls after adjustment for age, sex, cancer stage, and preference (<i>P</i> = .004). Compared with waitlist controls, both MBCR and TCQ groups had significantly improved fatigue with mean improvements of 3.66 and 3.42 points, respectively (MBCR: <i>P</i> = .036. TCQ: <i>P</i> = .043) and over 1 point of change on pain interference (MBCR: <i>P</i> = .029. TCQ: <i>P</i> = .002). MBCR and TCQ did not differ from one another. Preference status did not affect outcomes. Significant correlations were observed among changes in sleep, fatigue, and pain interference, suggesting mild to moderate associations.</p><p><strong>Conclusion: </strong>Compared with waitlist controls, MBCR and TCQ both improved fatigue and pain interference at post-intervention, and TCQ also improved sleep quality. Correlations across outcomes highlight the importance of addressing clusters of cancer symptoms within a whole-person health framework.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2929-2940"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.","authors":"Monzr M Al Malki, Stephanie Bo-Subait, Brent Logan, Janelle Olson, Jianqun Kou, Sarah Smith, Erin Leckrone, Juan Wu, Heather E Stefanski, Jeffery J Auletta, Stephen R Spellman, Craig Malmberg, Medhat Askar, Rachel Cusatis, Brian C Shaffer, Dipenkumar Modi, Farhad Khimani, Mahasweta Gooptu, Mehdi Hamadani, Abeer Madbouly, Martin Maiers, Stephanie Fingerson, Rachel Cook, Karen Ballen, Alison Loren, Karilyn Larkin, Sally Arai, Muna Qayed, Sung Won Choi, Larisa Broglie, Bronwen E Shaw, Steven Michael Devine, Antonio Martin Jimenez Jimenez","doi":"10.1200/JCO-26-02255","DOIUrl":"10.1200/JCO-26-02255","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2979"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.","authors":"Guang-Liang Chen, Yanjing Guo, Xin Liu, Ya'nan Yang, Youzhou Sang, Xueguan Lu, Si Sun, Xiao Shi, Yan Zhang, Tong-Zhen Chen, Ning Qu, Duo Wen, Xiao-Shuang Niu, Shu Dong, Yu Wang, Yulong Wang, Jiachen Wang, Lu Zhang, Chaosu Hu, Qinghai Ji, Dongmei Ji","doi":"10.1200/JCO-26-02254","DOIUrl":"10.1200/JCO-26-02254","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2979"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?","authors":"Linlin Xiao, Jingyi Sun, Fengpeng Wu","doi":"10.1200/JCO-26-00496","DOIUrl":"10.1200/JCO-26-00496","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2976-2977"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.","authors":"Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie G J Robbrecht, Jiří Tomášek, Cagatay Arslan, Mustafa Özgüroğlu, Panoraia Arni, Frederic Bigot, Sun Young Kim, Yoichi Naito, Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Ning Ma, Jeremy Scarato, Jeffrey S Ross, Holger Moch, Linda Mileshkin","doi":"10.1200/JCO-25-02974","DOIUrl":"10.1200/JCO-25-02974","url":null,"abstract":"<p><p>CUPISCO (ClinicalTrials.gov identifier: NCT03498521) demonstrated longer progression-free survival (PFS) with comprehensive genomic profiling (CGP) and subsequent molecularly guided therapies (MGTs), versus standard platinum-based chemotherapy, in patients with previously untreated, unfavorable cancer of unknown primary (CUP) who reached disease control after induction chemotherapy (three cycles). We report efficacy and safety after >1 year of additional follow-up. Eligible patients were randomly assigned (3:1) to MGT (investigator-chosen after discussion in a molecular tumor board) or three further cycles of chemotherapy. The primary end point was PFS. Secondary end points included overall survival (OS) and safety. At data cutoff (December 6, 2024), 436 patients were randomly assigned (326 to MGT; 110 to chemotherapy). Median follow-up was 37.0 months (range, 0.0-67.8). Updated median PFS was 6.1 months (95% CI, 4.7 to 6.5) with MGT and 4.4 months (95% CI, 4.2 to 6.4) with chemotherapy (hazard ratio [HR], 0.75 [95% CI, 0.59 to 0.95]; <i>P</i> = .017); median OS was 15.2 months (95% CI, 13.9 to 18.4) and 12.8 months (95% CI, 9.8 to 15.4), respectively (HR, 0.79 [95% CI, 0.61 to 1.02]; <i>P</i> = .0689). No new safety signals were identified. These updated results aligned with the primary analysis, demonstrating the benefit of CGP with subsequent MGT and highlighting the importance of incorporating CGP at initial diagnosis to guide treatment decisions for patients with unfavorable CUP.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2895-2902"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: \"Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?\" and \"Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?\"","authors":"Wentao Tang, Jianmin Xu","doi":"10.1200/JCO-26-00984","DOIUrl":"10.1200/JCO-26-00984","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2977-2978"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148584480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.","authors":"Ze-Qing Li, Song-Yang Wu, Li-Ping Ge, Xiang-Rong Wu, Wen-Ya Wu, Cheng-Lin Liu, Zhi-Ming Shao","doi":"10.1200/JCO-26-00261","DOIUrl":"https://doi.org/10.1200/JCO-26-00261","url":null,"abstract":"<p><strong>Purpose: </strong>Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the most common subtype, lacks simple, noninvasive biomarkers for recurrence. We evaluated circulating eosinophil count as a clinically applicable biomarker for recurrence in this population.</p><p><strong>Methods: </strong>Associations between preoperative eosinophil count and patient outcomes were evaluated in a multimodal discovery cohort (N = 472) and validated via propensity score overlap weighting in an independent expanded cohort (N = 23,170). We assessed the additive value of eosinophils in patients with 21-gene recurrence scores (RSs; n = 2,973) and their predictive role for adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in high-risk patients (n = 3,471). Mechanisms were investigated using integrated multiomics, spatial digital pathology, and in vivo preclinical models.</p><p><strong>Results: </strong>Higher circulating eosinophil counts correlated with significantly improved recurrence-free and distant metastasis-free survival in the discovery cohort. Genomic analysis associated these elevated counts with lower human leukocyte antigen homozygosity and increased intratumoral immune activation. Functionally, eosinophils were associated with antitumor effects, with evidence of CD8⁺ T-cell involvement. These findings were further validated in vivo, where eosinophil adoptive transfer significantly reduced tumor burden in both the EMT6 (BALB/c) and E0771 (C57BL/6) mouse models. Spatial profiling demonstrated that tumor-infiltrating eosinophils predominantly coaggregated with lymphocytes. These clinical associations were then validated in the independent expanded cohort through multivariable and propensity score-weighted analyses. Critically, eosinophil levels provided additive prognostic value beyond the 21-gene RS and, among high-risk patients, predicted the subset that would derive greater benefit from CDK4/6 inhibition.</p><p><strong>Conclusion: </strong>Circulating eosinophil count serves as a potential clinically applicable, liquid biopsy biomarker that independently prognosticates recurrence risk and predicts CDK4/6 inhibitor benefit, reflecting systemic immune activation in hormone receptor-positive/HER2- breast cancer.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600261"},"PeriodicalIF":44.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}